SAN FRANCISCO & PALO ALTO, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc., an innovator in treatment solutions for ear, nose and throat clinicians and patients, today reported data from its pivotal ...

The acquisition will allow Intersect ENT’s portfolio to support routine and complex procedures and positions the company to serve the growing market for ENT services, the statement said. It will also ...

MENLO PARK, Calif.--(BUSINESS WIRE)--Intersect ENT, Inc. (NASDAQ: XENT), a company dedicated to improving the quality of life for patients with ear, nose and throat conditions, today reported ...

Staying true to its pledge to crack down on potentially anticompetitive megamergers in the healthcare industry, the U.S. Federal Trade Commission has ordered Medtronic and Intersect ENT to adjust the ...

Medtronic said Friday that it has closed on a deal to acquire California-based Intersect ENT, one day after the Federal Trade Commission said the acquisition could move forward only if Medtronic ...

It may have taken an order from the Federal Trade Commission to get there—and Medtronic may be getting less bang for its buck than initially expected—but the medtech giant’s acquisition of Intersect ...

Intersect ENT has announced it has received FDA approval of the company’s second steroid-releasing product, according to a news release (pdf). The PROPEL mini is designed for localized drug delivery ...

A month has gone by since the last earnings report for Intersect ENT (XENT). Shares have lost about 0.6% in that time frame, outperforming the S&P 500. Will the recent negative trend continue leading ...

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the permanent loss of capital.' When we think about how risky a company is, we always like ...

A month has gone by since the last earnings report for Intersect ENT (XENT). Shares have added about 17.6% in that time frame, outperforming the S&P 500. Will the recent positive trend continue ...

A month has gone by since the last earnings report for Intersect ENT (XENT). Shares have lost about 18.6% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...